A clinical trial of amygdalin (Laetrile) in the treatment of human cancer (1982)

Peer-Reviewed Study · Charles G. Moertel, Thomas R. Fleming, Joseph Rubin, Larry K. Kvols, Gregory Sarna, Robert Koch, Violante E. Currie, Charles W. Young, Stephen E. Jones, J. Paul Davignon · January 28, 1982

Charles G. Moertel et al., 1982-01-28: NCI-sponsored trial of amygdalin (Laetrile) plus a metabolic-therapy programme in 178 patients with cancer, with no substantive benefit and documented cyanide toxicity. The authors conclude amygdalin is toxic and ineffective as a cancer treatment.

The hazards of amygdalin therapy were evidenced in several patients by symptoms of cyanide toxicity or by blood cyanide levels approaching the lethal range.

Abstract, unpaginated web record

Charles G. Moertel et al., 1982-01-28: NCI-sponsored trial of amygdalin (Laetrile) plus a metabolic-therapy programme in 178 patients with cancer, with no substantive benefit and documented cyanide toxicity. The authors conclude amygdalin is toxic and ineffective as a cancer treatment. Funder: National Cancer Institute sponsored the trial and its Pharmaceutical Resources Branch supplied the amygdalin (intravenous RS-amygdalin and oral R-amygdalin, from apricot pits); Mayo Clinic coordinated. Maker: drug made for NCI, not by a commercial sponsor. Comparator: none – single-arm, no placebo and no concurrent control; response judged against the patients' own baseline. Conflicts: the 1982 NEJM article carries no funding or disclosure statement. 179 patients entered, 1 ineligible, 178 treated, 175 evaluable for response. Authors note 42 Fed. Reg. 39768 (1977) context and that 27 states had legalised laetrile. Alternate host: NEJM https://www.nejm.org/doi/abs/10.1056/NEJM198201283060403 (paywalled). Study type: uncontrolled series.